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Engraftment syndrome (ES) encompasses a continuum of periengraftment complications after autologous
hematopoietic stem cell transplantation. ES may include noninfectious fever, skin rash, diarrhea, hepatic
dysfunction, renal dysfunction, transient encephalopathy, and capillary leak features, such as noncardiogenic
pulmonary inﬁltrates, hypoxia, and weight gain with no alternative etiologic basis other than engraftment.
Given its pleiotropic clinical presentation, the transplant ﬁeld has struggled to clearly deﬁne ES and related
syndromes. Here, we present a comprehensive review of ES in all documented disease settings. Furthermore,
we discuss the proposed risk factors, etiology, and clinical relevance of ES. Finally, our current approach to ES
is included along with a proposed treatment algorithm for the management of this complication.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION underlying mechanisms, and clinical relevance of ES.
Engraftment syndrome (ES) was ﬁrst deﬁned by Lee et al.
[1] in a retrospective analysis of 248 patients with cancer
undergoing autologous stem cell transplantation (ASCT).
Fifty-nine percent of patients developed a skin rash and
noninfectious fever, with amedian onset at 7 days post-ASCT.
Capillary leak, pulmonary inﬁltration, and hypoxia were also
commonly observed. ES has been documented in patients
undergoing ASCT or syngeneic SCT for multiple myeloma,
POEMS (Polyneuropathy, Organomegaly, Endocrinopathy,
Monoclonal protein, and Skin abnormalities) syndrome, light
chain amyloidosis, lymphoma, breast cancer, and multiple
sclerosis.
ES is now considered to be a formidable complication
after ASCT [2-4]. Although most cases of ES are mild and
resolve spontaneously or with corticosteroid therapy, ES can
occasionally be fatal. Although ES has been documented in
the transplant literature for more than 45 years, the etiology
of this syndrome remains incompletely understood. Updated
diagnostic criteria are necessary to standardize future
research in ES. Here, we review the literature on ES and
related syndromes and discuss potential risk factors,dgments on page 2067.
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ty for Blood and Marrow Transplantation.Furthermore, we include our current management approach
for the diagnosis and treatment of ES.DIFFERENTIAL DIAGNOSIS OF ES
The clinical features of ES have been deﬁned according to
diagnostic criteria of and Maiolino et al. [5] and Spitzer [6].
The Spitzer criteria were developed from a broad literature
review of ES-like syndromes in patients who had undergone
autologous, syngeneic, and allogeneic SCT. According to
Spitzer, the major criteria for ES were fever (101F),
erythrodermatous rash over more than 25% of the body not
linked tomedication, and noncardiogenic pulmonary edema.
Secondarily, ES is characterized by hepatic dysfunction (ie,
bilirubin 2 mg/dL or a 2-fold increase in transaminase over
baseline), renal insufﬁciency (ie, 2-fold increase in serum
creatinine over baseline), weight gain (ie, 2.5% increase), and
unexplained transient encephalopathy. A diagnosis of ES
requires the presence of all 3 major criteria or 2 major and 1
or more minor criteria within 96 hours of neutrophil
engraftment (Table 1). The Maiolino criteria were developed
from a single-center review of 125 patients who had un-
dergone autologous SCT. According to Maiolino et al., ES is
deﬁned as the development of a noninfectious fever in
combination with diarrhea, rash, or pulmonary inﬁltrates
within 24 hours of engraftment (Table 1).
Table 1
Criteria for Diagnosis of Engraftment Syndrome
Spitzer Criteria Maiolino Criteria
Requirements 3 Major or
2 major þ 1 minor
Major þ 1 minor
Major criteria Noninfectious fever, skin rash, or pulmonary edema Noninfectious fever
Minor criteria Weight gain, hepatic dysfunction, renal dysfunction,
or transient encephalopathy
Skin rash, pulmonary inﬁltrates, or diarrhea
Timing of symptoms relative to engraftment 4 Days within ANC .5  109/L 1 Day within neutrophils present
ANC indicates absolute neutrophil count.
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development of ES. Capizzi et al. [7] retrospectively assessed
signs of ES in ASCT patients who developed periengraftment
respiratory distress syndrome and found that symptoms
occurred within 5 days before or 4 days after engraftment.
Dispenzieri et al. [8] and Carreras et al. [2] found that
symptoms of ES were evident within 7 days of neutrophil
engraftment. Our group has found that symptoms most
commonly occur from 3 days before to 7 days after engraft-
ment [9].
Although no deﬁnitive biomarkers of ES have been
identiﬁed, elevated levels of C-reactive protein have been
associated with ES [2,10]. A fairly recent case report sug-
gested that expression of elaﬁn, a protein secreted by
epithelial cells in response to IL-1 and tumor necrosis factor-
a, may be an early biomarker of ES [11]. In more severe cases
of ES, the diagnosis can be conﬁrmed using a skin or colonic
biopsy to assess histology and mononuclear cell inﬁltrates
[12-16].ES: A SPECTRUM OF DISEASE SEVERITIES
Use of multiple nomenclatures in the ES literature has
complicated the ﬁeld. ES has been used synonymously with
capillary leak syndrome, autoaggression syndrome, perien-
graftment respiratory distress syndrome, and autologous
graft-versus-host disease (AGVHD) [7,17-19]. Each of these
syndromes encompasses all, or a subset, of symptoms that
have been attributed to ES (Figure 1). Although the ES
nomenclature appears to be widely accepted, the use of the
term “AGVHD” and the relationship between AGVHD and ES
is still debated.
Rappeport et al. [19] ﬁrst described evidence of an acute
cutaneous graft-versus-hostelike disorder after syngeneic
bone marrow transplants between identical twins forW
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Figure 1. Engraftment syndrome encompasses a spectrum of ASCT-associated
syndromes that vary in degrees of severity. PERDS indicates periengraftment
respiratory distress syndrome; CLS, capillary leak syndrome.leukemia. Hood et al. [20] reported a similar response in
patients undergoing either autologous or syngeneic bone
marrow transplant for leukemia or lymphoma. Skin biopsies,
taken 6 to 62 days post-transplant, showed histologic signs
of GVHD with features of altered polarity, dyskeratosis, and
basal vacuolization, with or without mononuclear cell inﬁl-
tration [19-21]. Although AGVHD cases involving only the
skin are typically self-limiting or managed with corticoste-
roids, more severe cases of AGVHD may affect the gastroin-
testinal (GI) tract and liver [12,13,20,22-24]. In 1 study, GI
AGVHD occurred in 13% of ASCT patients and was deﬁned by
persistent symptoms, mucosal abnormalities, and the pres-
ence of apoptotic crypt cells, with or without lymphoid in-
ﬁltrates, upon histologic examination [23]. In a subset of
these studies, rash and/or fever were noted in conjunction
with GI and liver involvement [13,22,24].
Despite overlapping symptoms observed in ES and
AGVHD, some investigators view AGVHD and ES as distinct
syndromes. For example, in a recent review of ES in the
context of both autologous and allogeneic transplantation,
Spitzer [25] suggested that ES be deﬁned as noninfectious
fever, capillary leak, and rash in the absence of histologic
evidence of GVHD. The diagnosis of ES, rather than AGVHD,
in past literature may be due to the lack of a tissue biopsy
conﬁrming classic GVHD pathology. In an attempt to unify
the ﬁeld, we propose that all forms of AGVHD (ie, cutaneous,
GI, and liver) be included under the umbrella of “engraft-
ment syndrome” (Figure 1). We encourage investigators and
clinicians, henceforth, to note the severity of ES based on
clinical symptoms and histologic evidence of immune
involvement.ES IN MULTIPLE MYELOMA
In a retrospective analysis by Katzel et al. [26] of 90 pa-
tients with multiple myeloma who received ASCT after
melphalan therapy, 10% of patients developed ES according
to the Spitzer or Maiolino criteria. All patients developed a
noninfectious fever, and 8 of 9 had diarrhea. A skin rash was
evident in 4 patients, whereas pulmonary inﬁltrates were
seen in 6 patients. Three of 4 patients who developed hyp-
oxia responded to high-dose steroids, whereas the remaining
patient died of multisystem failure. This patient did not
receive steroid therapy until day 17. The incidence of ES
reached 29% (13/45) in Maiolino et al.’s cohort of patients
with myeloma [5].
Giralt et al. [27] reported 14 patients with myeloma who
developed varied degrees of ES/AGVHD after ASCT and
cyclosporine (CsA) treatment. Speciﬁcally, 10 patients
developed mucositis, 8 patients developed kidney or liver
complications, and 4 developed cardiac problems. Histologic
signs of acute GVHD were evident in 7 patients. One patient
was diagnosed with clinically and histologically evident
GVHD and was responsive to steroid therapy. In our
R.F. Cornell et al. / Biol Blood Marrow Transplant 21 (2015) 2061e2068 2063retrospective analysis of 421 patients with myeloma, the
incidence of ES reached 21% [9]. The most common symp-
toms were fever, diarrhea, and rash. Symptoms resolved
spontaneously or with corticosteroid treatment in most pa-
tients (95%).
In contrast to most studies that document mild, treatable
cases of ASCT-associated ES, our group reported the devel-
opment of severe ES/AGVHD in patients undergoing ASCT
[13]. Severe ES occurred in 5 of 223 patients (2%) with
myeloma. Three of the 5 patients who developed complica-
tions were undergoing a second ASCT. Histologic signs of
GVHD were seen in the skin, liver, and/or GI tract. Lympho-
cytes, mononuclear cells, and neutrophils were reported in
liver and GI biopsies. Histologic GVHD occurred on average
within the ﬁrst 2 weeks and commonly followed signs of ES.
Patients were only partially responsive to steroid therapy,
and 4 died because of complications from ES/AGVHD or from
tumor relapse. In agreement with this study, Goddard et al.
[22] reported a fatal case of multiorgan (ie, skin, GI, liver),
steroid-resistant AGVHD in a single myeloma patient un-
dergoing secondary ASCT. Liver and digestive tract biopsies
after day 41 were indicative of grade IV GVHD and showed
evidence of immune inﬁltration by lymphocytes and neu-
trophils. In a review of 388 ASCT patients, Cogbill et al. [12]
reported the development of ES/AGVHD in 17 patients (4%),
16 of which were patients with myeloma. Grades I to IV
GVHD was diagnosed in biopsies from skin, liver, small in-
testine, and, most commonly, colon. Six of 16 patients died
from sepsis (n¼ 4), central nervous system hemorrhage (n¼
1), or relapse of disease (n ¼ 1). Collectively, these data
highlight the potential for serious complications in patients
who develop ES and encourage early detection and
treatment.
ES AND POEMS SYNDROME
In a retrospective analysis of 30 POEMS patients who
underwent ASCT, fever, diarrhea, weight gain, and rash were
observed in 93%, 77%, 53%, and 43% of patients, respectively
[8]. ES was found to occur in 27% to 47% of patients
depending on the criteria used [8]. The onset of ES symptoms
occurred at a median of 9 days. When the required time to
engraftment, based on Maiolino and Spitzer criteria, was
broadened, the rate of ES surpassed 50%. The authors sug-
gested that these patients might be highly susceptible to ES
because of a pre-existing aberrant cytokine milieu (vascular
endothelial growth factor, tumor necrosis factor-a, IL-1b)
that is exaggerated by ASCT [8].
Jimenez-Zepeda et al. [28] reported the outcome of 8
patients with POEMS who had undergone ASCT. In contrast
to the previous study, only 37.5%, 12.5%, 25%, and 50% of
patients developed fever, diarrhea, weight gain, and rash,
respectively. Here, none of the patients developed ES, as
strictly deﬁned by Spitzer and Maiolino criteria. Importantly,
prednisone was given to all patients before ASCT in this
study. In the previous analysis [8], only 43% of the patients
received corticosteroid therapy. Taken together, these studies
emphasize the importance of monitoring for ES in patients
undergoing ASCT therapy for POEMS and suggest that early
treatment with corticosteroids may be beneﬁcial.
ES IN LIGHT CHAIN AMYLOIDOSIS
Irazabal et al. [29] reported ES in 29 of 377 patients (8%)
who underwent ASCT for amyloidosis. Acute kidney injury,
edema, fever, diarrhea, rash, and transient encephalopathy
were observed in 93%, 93%, 83%, 69%, 48%, and 17% ofpatients, respectively. Carerras et al. [2] reported a high
incidence (12/25; 48%) of ES in patients with amyloidosis. In
a prospective study, Sanchorawala et al. [30] reported evi-
dence of AGVHD in 2 of 30 patients with amyloidosis after
ASCT with high-dose melphalan plus bortezomib as
conditioning.
ES IN OTHER DISEASE SETTINGS
Moreb et al. [18] reported an “autoaggression syndrome”
in patients with breast cancer or lymphoma who had
undergone ASCT. This syndrome was deﬁned by the devel-
opment of a skin rash that presented 5 to 13 days post-
transplant. This ASCT-related skin rash was more
frequently observed in patients with breast cancer (20/30;
67%) compared with patients with lymphoma (3/12; 25%).
Fever was evident in 18 patients and was more prevalent in
the breast cancer cohort (57% versus 8%). Six of 10 patients
showed evidence of grades I to II GVHD by skin biopsy [18].
In a large retrospectively analysis of 452 lymphoma pa-
tients, Keung et al. [31] found evidence of ES or AGVHD in 40
of 452 patients (9%) after ASCT. We observed a frequency of
10% in our retrospective analysis of 170 patients with lym-
phoma [9]. ES has also been documented in patients under-
going ASCT for multiple sclerosis. Carerras et al. [32] noted
the development of ES, characterized by noninfectious fever,
skin rash, and weight gain, in 3 of 15 patients (20%) under-
going ASCT for multiple sclerosis. ES symptoms were readily
resolved with corticosteroid therapy in these patients.
Although ASCT is commonly used in cases of autoimmune
disease, corticosteroids are regularly used as a maintenance
therapy in these patients and may prophylactically reduce
the risk of ES.
RISK FACTORS FOR ES
Elucidation of the risk factors for ES has been hindered by
variations in patient populations, subject number, pretreat-
ment regimens, and lack of clearly deﬁned disease criteria.
Numerous risk factors for ES have been suggested in the
literature. A correlation with female gender has been sug-
gested but has not been consistent in all reports [2,33]. In
their initial deﬁnition of ES, Lee et al. [1] noted a positive
correlation between post-transplant granulocyte colony-
stimulating factor (CSF) therapy and development of ES;
however, this association has not been conﬁrmed in more
recent studies [18]. Akasheh et al. [34] found that ES was
more common in breast cancer patients who received
granulocyte-macrophage CSF (8/10) compared with gran-
ulocyte CSF (4/9). Similarly, a recent presentation at the
American Society for Blood and Marrow Transplantation
tandem meetings in San Diego regarding patients undergo-
ing ASCT for myeloma suggested that granulocyte-
macrophage CSF treatment was associated with a higher
risk of ES (28% versus 3%; odds ratio, 12.5; P ¼ .001) [35].
Conﬂicting reports have been published assessing the role of
CD34þ cell number and engraftment rate in development of
ES [9,33,34,36]. Of note, a comparison of CD34þ donor cells
from patients who developed ES/AGVHD (n¼ 9) versus those
who did not (n¼ 42) revealed increased expression of GATA-
2 and CD130 and decreased expression of CXCR4, suggesting
the phenotype of donor cells may play a role [37].
A number of studies have attempted to link the devel-
opment of ES with various pretreatment regimens.
Although Ravoet et al. [36] showed a correlationwith the use
of busulfan, González-Vicent et al. [38] found the opposite
to be true. Jimenez-Zepeda et al. [28] suggested that
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reduced incidence of ES in patients with POEMS. The inter-
pretation of these results was complicated by the fact that all
patients also received prednisone before ASCT [28]. How-
ever, in support of their ﬁndings, our assessment of pre-
treatment regimens in patients with myeloma or lymphoma
revealed that cyclophosphamide exposure was associated
with reduced risk for ES [9]. Of interest, Carreras et al. [2]
showed in a broad spectrum of patients that a less aggres-
sive history of chemotherapy was associated with a higher
risk of ES. In linewith this theory, Moreb et al. [18] found that
patients undergoing ASCT for breast cancer were more likely
to develop ES if they had previously undergone only a single
round of chemotherapy or radiotherapy. Furthermore, in
patients with myeloma, previous exposure to bortezomib or
lenalidomide, rather than broad cytotoxic chemotherapies,
was linked to a higher risk of ES [9]. Future large, multicenter
studies using the current criteria are necessary to more
accurately deﬁne the risk factors for ES across the broad
spectrum of patients undergoing ASCT.
MECHANISMS OF ES
The mechanisms responsible for ES/AGVHD development
are poorly understood. Although a number of studies suggest
that ES can be reversed by corticosteroid therapy, controlled
trials have not been performed to directly assess the beneﬁt
of corticosteroids [39]. Nevertheless, a number of studies in
animal models and humans suggest that the immune system
plays a role in the development of ES, despite the absence of
HLA and minor histocompatibility antigen mismatch.
Early work in the Lewis rat model showed that a GVHD-
like syndrome occurred after transplantation of syngeneic
bone marrow into irradiated recipients that received CsA
post-transplant. Speciﬁcally, irradiated rats received a bone
marrow graft and were treated with CsA for 20 to 40 days
post-transplant after engraftment was complete. Syngeneic
GVHD (SGVHD) developed 12 to 40 days after the last CsA
treatment [40-42]. In this model, SGVHD was delayed in the
absence of CD4þ T cells and completely inhibited in the
absence of CD8þ T cells [43,44]. Furthermore, the authors
showed that MHC-IIespeciﬁc antibodies signiﬁcantly
delayed the development of SGVHD [44]. Analysis of the TCR
repertoire in this model revealed that Vb8.5þ T cells were
predominant in SGVHD lesions and more frequent in rats
treated with CsA, suggesting that T cell selection is skewed in
the presence of CsA [45]. In support of this hypothesis, CsA is
known to alter T cell development and selection in the
thymus [46]. Induction of SGVHD required that the recipient
undergo high-dose irradiation and CsA treatment, and
transfer of the disease required an irradiated recipient. Of
interest, SGVHD was abrogated if the disease-promoting T
cells were transferred with CD4þ T cells from untreated
normal littermates [47]. These studies suggest that a
radiation-sensitive CD4þ T cell is necessary for controlling
the development of SGVHD.
A number of clinical trials were designed based on the
knowledge gained from the Lewis rat model. In an early
study by Jones et al. [48], CsA appeared to induce cutaneous
GVHD in 5 patients after autologous transplant. Of interest,
peripheral blood lymphocytes isolated post-transplant dis-
played cytotoxic capacity against autologous lymphocytes
that were recovered from peripheral blood before the start of
treatment. This autoreactivity was not observed in lympho-
cytes isolated from peripheral blood after resolution
of AGVHD or in patients not induced with CsA. Blockingantibodies speciﬁc for MHC-II and the invariant chain
(Call II-associated invariant chain [CLIP]) inhibited T cell
cytotoxicity ex vivo [48,49]. Thus, in agreement with the rat
model, CsA-induced AGVHD depends on recognition of
MHC-II, presumably by T cells that hold a relatively high af-
ﬁnity for self-MHC and have escaped negative selection. To
further investigate the role of the T cell response in AGVHD,
Massumoto et al. [50] compared the incidence of AGVHD in
patients before or after treatment with IL-2. IL-2 treatment
was given for 5 consecutive days 25 to 58 days post-
transplant. The incidence of AGVHD increased from 30% (3/
10) at baseline to 79% (11/14) after treatment with IL-2. In
this scenario IL-2 may have enhanced an ensuing autor-
eactive T cell response or encouraged a break in tolerance.
Importantly, in the absence of a control group, it is difﬁcult to
determine whether this delayed presentation of AGVHD was
mediated by IL-2 [50]. Although CsA induction studies of
SGVHD/AGVHD provided valuable insight into the mecha-
nism of this disorder, the penetrance of CsA-induced AGVHD
is highly variable in humans, suggesting that genetic vari-
ability and disease history in patients play an important role.
In line with the Lewis rat model, Rappeport et al. [19]
hypothesized that suppressive T cells, perhaps analogous to
regulatory T cells (Tregs), would be eliminated by irradiation
and prior chemotherapy in patients undergoing syngeneic or
ASCT. In the absence of these suppressive Tcells, autoreactive
T cells would be free to target “self” in the immune-ablated
graft recipient [19,51]. Of interest, mobilization of stem
cells with cyclophosphamide is known to enrich for Tregs,
whereas lenalidomide has been shown to inhibit Treg pro-
liferation and suppressive function in vitro [52,53]. The
immune-modulatory effects of these pretreatment regimens
may explain the respective negative and positive associa-
tions with risk of ES. A detailed analysis of in vivo immune
modulatory effects of broad cytotoxic regimens and more
targeted therapies (ie, bortezomib and lenalidomide) may
shed light on the role of immune ablation in ES.
Engraftment of neutrophils and other myeloid derived
cells generally occurs within 2 weeks, whereas T cell
engraftment is not complete until 2 months after autologous
transplant with CD34þ peripheral blood stem cells [54]. ES is
deﬁned, in part, by early presentation of symptoms that
coincide with neutrophil engraftment. Surprisingly, the
presence of neutrophils and other innate immune cells in
skin grafts has rarely been assessed. Kennedy et al. [55] noted
that AGVHD was evident in their CsA-treated patients before
the appearance of leukocytes in the blood. This is in sharp
contrast to the rat model of SGVHD where T cells are fully
reconstituted before CsA treatment. Lymphocytic inﬁltrates
have been noted in biopsies from patients with more
aggressive AGVHD. In the study by Goddard et al. [22], the
biopsy was taken 41 days post-transplant when T cells
reconstitution would be nearly complete. Our group has also
noted lymphocytic inﬁltrates at 26 days post-transplant [13].
Lee et al. [1] performed immunohistochemistry to charac-
terize inﬁltrating immune cells in skin biopsies from patients
who developed ES after bone marrow or peripheral stem cell
transplants. Perivascular mononuclear cells inﬁltrates were
composed primarily of cells expressing CD2 (natural killer
[NK] and T cells), CD4 and CD3 (T cells), and CD5 (B and T
cells), and showed low levels of CD8 (T, NK, and dendritic
cells), CD16 (neutrophils and NK cells), and CD56 (NK cells).
Importantly, the presence of contaminating lymphocytes in
the transplant was not assessed and the time of biopsy
acquisition was not reported [1]. A prospective, detailed
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ASCT with puriﬁed CD34þ cells would shed light on the role
of both the innate and adaptive immune response in ES
development and progression.
Overall, mechanistic studies of ES in humans have been
sparse. We suggest that, even in the absence of HLA
mismatch, the principles of allogeneic GVHD may be appli-
cable to ES [56] (Figure 2). Proinﬂammatory cytokines (ie, IL-
1, tumor necrosis factor-a, and IFN-g) and innate immune
cells likely play a role in the initial stages of ES [6,57]. These
cytokines predispose patients to heightened antigen pre-
sentation and T cell activation in the allogeneic setting and
may contribute to a break in peripheral tolerance in the
autologous setting. Spontaneous resolution in mild cases of
ES likely coincides with tissue repair and completion of
engraftment. More aggressive presentations of ES may occur
in patients with a predisposition to self-reactivity as the
lymphocytes are reconstituted. In these patients T cells that
recognize self-MHC and self-peptide may evade central
tolerance and become cytotoxic in the absence of effective
peripheral regulation. At later stages of engraftment, pe-
ripheral regulatory mechanisms are restored, allowing
spontaneous remission of symptoms. Those patients who
succumb to ES may fail to regenerate these regulatory
mechanisms. Of note, efﬁcient Treg reconstitution has been
associated with reduced risk of allogeneic GVHD [58]. Future
characterization of the cytokines milieu, immune inﬁltrate,
and Tregs in patients with ES is necessary to validate this
hypothetical model.
CLINICAL IMPLICATIONS OF ES
It has been postulated that an ES-associated graft-versus-
tumor effect may ensue in patients undergoing ASCT,
contributing to improved survival in cancer patients [59].
Survival outcomes are rarely reported in the ES literature. In
a single case report, Byrne et al. [60] reported a possible
graft-versus-myeloma effect, as evidenced by a reduction in
Bence-Jones protein excretion to .08 g/dL and <2% plasma
cell inﬁltration in a bone marrow aspirate. In sharp contrastFigure 2. Hypothetical mechanisms of ES. Proposed stages and severities of ES after A
each stage. Neutrophil and T cell engraftments are complete by days 14 and 56, respect
dendritic cell; CD4, helper T cell; CD8, cytotoxic T cell; B, B cell; NE, normal epitheliuto this case, a review of 461 lymphoma patients by Keung
et al. [31] failed to show improved survival in patients who
developed ES and instead revealed an association between
ES/AGVHD and the development of a secondary myelodys-
plastic syndrome. Similarly, Khan et al. [61] studied the as-
sociation between disease outcome and ES in 85 patients
with breast cancer and reported that disease-related mor-
tality was higher in relapsed patients who developed ES
during ASCT. Our review of 591 patients undergoing ASCT for
myeloma or lymphoma found no association between
development of ES and mortality, relapse, or survival [9].
Early studies, performed shortly after the discovery of
AGVHD and SGVHD, attempted to augment this phenome-
non to generate an antitumor effect [47]. As seen in the rat
models of CsA-induced AGVHD, Yeager et al. [62] reported
that 15 of 19 patients (79%) undergoing SCT for chronic
myelogenous leukemia developed ES/AGVHD after post-
transplant treatment with 1 mg/kg CsA. Kennedy et al. [55]
found that CsA induced ES/AGVHD in a dose-dependent
manner in patients with breast cancer. One of 7 (14%), 21 of
31 (68%), and 12 of 13 (92%) patients developed ES/AGVHD
when treated with 1 mg/kg, 2.5 mg/kg, or 3.75 mg/kg CsA,
respectively. Although the rate of ES/AGVHD induction with
2.5 mg/kg CsA was not increased with the addition of IFN-g
(56%), a larger proportion of patients developed a more se-
vere rash (grades 2 and 3) [63].
A small study (n ¼ 17) by Ratanatharathorn et al. [64]
suggested that IFN-a treatment could enhance CsA-induced
ES/AGVHD. Speciﬁcally, the incidence of grades II/III GVHD
increased from 50% (2/4) in CsA-induced patients to 100% (8/
8) in those receiving CsA in combination with IFN-a. Of note,
all 4 patients who received IFN-a alone also developed
grades II/III GVHD [64]. Bolanos-Meade et al. [65] reported
the ﬁrst controlled trial comparing untreated or CsA-induced
patients. Fifty-one patients with lymphoma were evaluated
in a prospective trial for any beneﬁt of CsA-induced AGVHD.
Unfortunately, only 4 of the 24 patients who received CsA
developed AGVHD, and no conclusions could be drawn from
such a small population.SCT are modeled. Predicted cytokine and leukocyte involvement is shown for
ively. TNF indicates tumor necrosis factor; Mac, macrophage; N, neutrophil; DC,
m.
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Investigators who question the premise that ES is a true
clinical entity have introduced additional controversy in the
ﬁeld. The major arguments for this stance are that ES is an
artifact of nontransplant-related complications (ie, infection
and pretreatment toxicity), that the features of ES and
AGVHD overlap, and that the incidence of ES is not uniform
among the disease subtypes [66]. Although it is possible that
some cases of ES may be explained by post-transplant
complications, in the most stereotypical cases of ES, the
onset of fever, rash, and diarrhea invariably occurs during or
after neutrophil engraftment when the risk of infection is
actually decreased. In our experience many of these patients
failed to exhibit evidence of infection before or concurrent
with the development of ES. Furthermore, ES does not occur
during bone marrow recovery in a nontransplant setting (ie,
chemotherapy), suggesting that stem cell transplant is
required. Second, in those patients for whom biopsies are
performed for evaluation of diarrhea, the pathologic ﬁndings
are typically indistinguishable from what is observed with
allogeneic GVHD. As discussed above, we believe ES en-
compasses a continuum of disease severities, including more
severe, sometimes fatal, cases with histologic evidence of
GVHD. We suggest that the overlap of symptoms with
AGVHD, on the contrary, proves the existence of ES. This
controversy is rooted in semantics of nomenclature rather
than in evidence of clinical relevance. Third, the lack of a
uniform incidence across disease subtypes can be explained
by differences in the underlying disease, prior therapy, and
inherent patient susceptibility. Wewould concur with othersFigure 3. Our management approach to ES. ISthat the pathophysiology of ES requires further elucidation.
Our view remains that ES is a complication that occurs in a
signiﬁcant percentage of ASCT recipients. Appropriate
awareness and management of this problem is essential to
reduce patient morbidity and, in some cases, mortality.
OUR MANAGEMENT APPROACH TO ES
The most important aspect in management of ES is early
recognition of the deﬁned clinical features according to the
Spitzer and Maiolino criteria (Table 1). It is important to
recognize that a subset of patients, including those with
POEMS, may have ES up to 7 days before engraftment and
thus not follow these criteria [8]. Also, in patients who pre-
sent with more severe symptoms, early signs of ES at the
time of neutrophil engraftment may have been overlooked.
In these cases a diagnosis of ES should be suspected based on
the clinical criteria regardless of the timing of symptoms
relative to engraftment. In our study approximately 95% of
patients developed symptoms consistent with ES between 3
days before and 7 days after engraftment.
Our ﬁrst step inmanagement of suspected ES is to exclude
alternative causes (Figure 3). Patients should be treated with
broad-spectrum antibiotics while ruling out infection. In
addition, the potential etiology for drug-induced rash should
be assessed. Causes for medication-and infection-induced
diarrhea should be evaluated. Features of capillary leak and
ﬂuid overload should be conﬁrmed to be independent of i.v.
ﬂuid administration. Brain natriuretic peptide assessment
can be helpful to evaluate for possible cardiac etiology. In
many cases clinical features of ES will resolve spontaneously.T indicates immunosuppressive therapy.
R.F. Cornell et al. / Biol Blood Marrow Transplant 21 (2015) 2061e2068 2067If symptoms are not improved after 48 to 72 hours, a diag-
nosis of ES should be considered. The decision to treat is
based on the severity of symptoms and judgment of the
treatment provider that other etiologies are excluded and
treatment is warranted.
When treatment is indicated, we suggest initiation of
methylprednisolone 1 to -1.5 mg/kg/day until symptoms
begin to resolve, which typically occurs within 2 to 3 days,
followed by a reduction to 40 to 50 mg p.o. prednisone a day
for 2 to 3 days. Oral prednisone can then be tapered 10 mg
every 2 to 3 days as long as symptoms continue to resolve.
Alternatively, methylprednisolone may be reduced to .5 mg/
kg/day, followed by a slower taper of 10mg/day. We ﬁnd that
early intervention with corticosteroids is sufﬁcient to miti-
gate progression to more severe manifestations [9]. If clinical
features have not improved 72 hours after initiation of cor-
ticosteroids, further evaluation is warranted. In
corticosteroid-refractory cases, we recommend biopsy of the
site of end-organ damage: skin biopsy for skin rash, colon
biopsy for severe diarrhea, and/or liver biopsy for liver
function test abnormalities. If the diagnosis of ES is
conﬁrmed histologically, additional immune suppressants
should be administered until symptoms subside. If an alter-
native etiology is found, patients should be managed
accordingly.
FUTURE DIRECTIONS
Future studies are required to better characterize the risk
factors and underlying mechanisms in ES. Development of a
grading system, such as that for National Institutes of Health
criteria for acute and chronic GVHD, would be a useful guide
for determination of management decisions for ES. Basic
immunohistochemistry studies are necessary to identify the
speciﬁc leukocyte populations (eg, myeloid lineage, NK cells,
Tregs, CD4þ T cells, and CD8þ T cells) contributing to early
and late stages of ES. Larger prospective analyses of elaﬁn
and inﬂammatory cytokines in peripheral bloodmay conﬁrm
the role of such biomarkers in predicting ES. New biomarkers
may be identiﬁed through molecular proﬁling of archived
hematopoietic stem cells from ES-positive and ES-negative
patients. Collectively, these studies will improve diagnosis
and treatment of ES.
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